Mylan Laboratories Inc. is prepared to produce significant volumes of Tamiflu, a pharmaceutical product produced by Roche Holdings AG. Tamiflu, which is used to treat flu symptoms, is in high demand based on global concerns over a potential avian flu pandemic.
According to a company release, Mylan was contacted by United States Senator Charles Schumer, D-N.Y., and the company intends to immediately begin working with political leaders, the United States Food and Drug Administration and Roche to respond to this global health situation.
Robert J. Coury, Mylan's vice chairman and chief executive officer said, "Mylan is uniquely positioned to respond to this need for increased production of Tamiflu. We have always structured our manufacturing capacity to be able to rapidly respond to urgent needs such as this one and we stand ready to contribute to the production of this important medication."
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.